📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
RPG Life Sciences Recommends ₹24 Dividend and Appoints New Independent Director
RPG Life Sciences has recommended a final dividend of ₹24 per equity share (300% of face value) for the financial year ended March 31, 2026. The company also announced the appointment of Dr. Pratit Samdani, a renowned physician, as an Additional Non-Executive Independent Director for a five-year term. This announcement follows a regulatory filing to provide financial results in a machine-readable format, confirming that there are no changes to the previously reported audited figures. The board has confirmed unmodified audit opinions for both standalone and consolidated financial statements.
Key Highlights
Recommended a final dividend of ₹24 per equity share of face value ₹8 (300%) for FY 2025-26.
Appointed Dr. Pratit Samdani as Additional Non-Executive Independent Director from April 29, 2026, to April 28, 2031.
Audited financial results for Q4 and FY26 confirmed with an unmodified opinion from statutory auditors SR BC & CO LLP.
Resubmitted financial results in machine-readable/searchable form as per NSE request with zero changes to original data.
💼 Action for Investors
Investors should track the upcoming Annual General Meeting for the final approval of the ₹24 dividend. The appointment of a medical expert to the board is a positive step for governance in a life sciences company.
Loading analysis...
RPG Life Sciences Recommends ₹24 Dividend and Appoints Dr. Pratit Samdani as Director
RPG Life Sciences has recommended a substantial final dividend of ₹24 per equity share (300% of face value) for FY 2025-26, pending shareholder approval. The company reported its audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. In a strategic move, the board appointed Dr. Pratit Samdani, a highly respected physician, as an Additional Non-Executive Independent Director for a five-year term. The company also updated its internal code for fair disclosure and insider trading monitoring.
Key Highlights
Recommended a dividend of ₹24 per equity share of face value ₹8, representing a 300% payout.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Appointed Dr. Pratit Samdani as an Independent Director for a 5-year term until April 2031.
Statutory auditors issued a report with an unmodified opinion on the company's financial statements.
Amended the Code of Fair Disclosure and internal procedures for regulating trading by designated persons.
💼 Action for Investors
Investors should benefit from the significant dividend payout and may view the addition of a medical expert to the board as a positive for the company's long-term strategic growth in the pharma sector. Maintain a watch on the upcoming AGM for the final dividend approval and payment timeline.
Loading analysis...
RPG Life Sciences Recommends Rs 24 Dividend; Sets June 19 as Record Date
RPG Life Sciences has recommended a final dividend of Rs. 24 per equity share for FY 2025-26, which represents a 300% payout on the face value of Rs. 8. The company has fixed June 19, 2026, as the record date for determining shareholder eligibility for this dividend, pending AGM approval. Alongside the financial results, the board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term. The dividend is expected to be paid within 30 days of the Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs. 24 per equity share (300% of face value)
Fixed June 19, 2026, as the record date for dividend entitlement
Approved audited standalone and consolidated financial results for FY 2025-26
Appointed Dr. Pratit Samdani as Independent Director for a 5-year term until 2031
Dividend payment to be completed within 30 days of shareholder approval at the AGM
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock prior to the record date of June 19, 2026. The 300% dividend payout indicates a strong commitment to returning capital to shareholders.
Loading analysis...
RPG Life Sciences Q4 Revenue Jumps 23.6%, Recommends 300% Dividend
RPG Life Sciences reported a strong Q4 FY26 with revenue growing 23.6% YoY to ₹176.9 crores and a healthy EBITDA margin of 25.6%. The Domestic Formulations business outperformed the Indian Pharma Market by 1.8 times, growing at 18.2% in Q4. A significant highlight was the API division's 144.3% growth, marking a full recovery after operations were impacted by a fire in early 2025. The company also announced a substantial final dividend of ₹24 per share for the fiscal year.
Key Highlights
Q4 FY26 Revenue rose 23.6% YoY to ₹176.9 crores with an EBITDA margin of 25.6%
Domestic Formulations grew 18.2% in Q4, outpacing the Indian Pharma Market growth of 10.1%
API division revenue surged 144.3% in Q4 FY26 following the restoration of the manufacturing facility
Full-year FY26 revenue reached ₹707.5 crores, up 8.3% from ₹653.4 crores in FY25
Recommended a final dividend of ₹24 per equity share (300% on face value of ₹8)
💼 Action for Investors
The stock remains attractive due to its consistent market-beating growth in domestic formulations and the successful turnaround of the API segment. Investors should monitor the company's expansion into new global markets and its new product pipeline for long-term value creation.
Loading analysis...
RPG Life Sciences Recommends Rs 24 Dividend and Appoints New Independent Director
RPG Life Sciences has recommended a substantial dividend of Rs 24 per equity share (300% of face value) for the financial year 2025-26. The Board approved the audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. To strengthen its leadership, the company appointed Dr. Pratit Samdani, a renowned physician and researcher, as an Independent Director for a five-year term. Additionally, the company updated its code of conduct for fair disclosure and insider trading monitoring.
Key Highlights
Recommended a dividend of Rs 24 per equity share of face value Rs 8 (300% payout) for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Appointed Dr. Pratit Samdani as Additional Non-Executive Independent Director for a 5-year term starting April 29, 2026.
Updated the Code of fair disclosure and internal procedures for regulating and reporting trading by designated persons.
💼 Action for Investors
Investors should welcome the high dividend payout as a sign of strong cash flow and management's commitment to shareholder returns. The addition of a medical expert to the board adds significant domain expertise to the company's governance.
Loading analysis...
RPG Life Sciences Recommends ₹24 Dividend (300%) and Appoints New Independent Director
RPG Life Sciences has recommended a substantial final dividend of ₹24 per equity share (300% of face value) for the financial year 2025-26. The board approved the audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. Additionally, the company has strengthened its board by appointing Dr. Pratit Samdani, a highly respected physician and researcher, as an Additional Non-Executive Independent Director for a five-year term. This appointment is expected to bring deep clinical and research expertise to the company's strategic oversight.
Key Highlights
Recommended a final dividend of ₹24 per equity share of face value ₹8, representing a 300% payout.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a 5-year term until April 2031.
The statutory auditor's report for the financial year was issued with an unmodified opinion.
Updated the Code of Fair Disclosure and internal procedures for regulating trading by designated persons.
💼 Action for Investors
Investors should benefit from the significant dividend payout and the addition of specialized medical expertise to the board. Maintain a positive outlook while reviewing the detailed financial performance in the upcoming annual report.
Loading analysis...
RPG Life Sciences Clarifies Identical Q3 Results; API Division Spin-off to Subsidiary Underway
RPG Life Sciences clarified to the NSE that its standalone and consolidated financial results for Q3 FY26 are identical because its new subsidiary, RPG Active Pharma Limited, only commenced operations on January 6, 2026. The company reported a Q3 revenue of ₹18,003 Lakhs and a Profit After Tax of ₹2,213 Lakhs. Results were impacted by a one-time exceptional charge of ₹1,108 Lakhs due to the implementation of New Labour Codes. The internal reorganization to transfer the API division is expected to be completed by February 2026 to streamline business focus.
Key Highlights
Q3 FY26 Revenue from operations stood at ₹18,003 Lakhs, a growth from ₹17,271 Lakhs in the previous year's corresponding quarter.
Net Profit for the quarter was ₹2,213 Lakhs, after accounting for a ₹1,108 Lakhs exceptional expense for New Labour Code obligations.
The company is transferring its API division to a new wholly-owned subsidiary, RPG Active Pharma Limited, incorporated on December 24, 2025.
Insurance recovery for the January 2025 fire incident is progressing, with ₹2,050 Lakhs received against a total loss of ₹2,295 Lakhs.
Nine-month FY26 Revenue reached ₹53,063 Lakhs with a Net Profit of ₹8,527 Lakhs.
💼 Action for Investors
Investors should monitor the completion of the API division transfer and its impact on operational efficiency. The exceptional hit from the New Labour Code is a one-time regulatory adjustment and does not reflect on core business performance.
Loading analysis...
RPG Life Sciences Q3 FY26: Revenue Up 4.2% to ₹180 Cr, PAT Declines 20% YoY
RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.
Key Highlights
Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.
PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.
Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.
API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.
The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.
💼 Action for Investors
The significant margin contraction and the fire-related disruption in the API segment are short-term negatives. Investors should watch for the recovery of API operations and the impact of the ₹140 crore capex on future growth before increasing exposure.
Loading analysis...
RPG Life Sciences Q3 FY26: Revenue up 4% to ₹180 Cr; PAT drops 20% on API Segment Fire Disruption
RPG Life Sciences reported a modest 4.2% YoY revenue growth to ₹180.0 crore for Q3 FY26, but profitability faced significant pressure. PAT declined by 19.8% to ₹27.9 crore, and EBITDA margins contracted from 30.4% to 24.0% YoY. The performance was primarily dragged down by the API segment, which saw a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite this, the Domestic Formulations business grew 8.9% and the company remains debt-free with a ₹140 crore capex plan for global expansion.
Key Highlights
Q3 FY26 Revenue grew 4.2% YoY to ₹180.0 Cr, while 9M FY26 Revenue reached ₹530.6 Cr (+4% YoY).
PAT for Q3 FY26 fell 19.8% to ₹27.9 Cr, and EBITDA declined 17.7% to ₹43.2 Cr.
API segment revenue for 9M FY26 dropped 19.4% to ₹61.7 Cr following a fire incident in a manufacturing block.
Domestic Formulations (71% of total sales) grew 8.9% in 9M FY26, reaching ₹364.6 Cr.
Company remains debt-free and is executing a ₹140 Cr capex for international market expansion.
💼 Action for Investors
Investors should monitor the timeline for the full restoration of the API manufacturing block and the impact of the ₹140 crore capex on future growth. While the domestic business remains a strong anchor, the short-term margin compression warrants a cautious approach until API operations normalize.
Loading analysis...
RPG Life Sciences Q3 FY26 Revenue Up 4.2% Y-o-Y to Rs 180 Cr; EBITDA Margin at 24%
RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.
Key Highlights
Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
EBITDA margin remained robust at 24.0% for the quarter
Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores
💼 Action for Investors
Investors should take note of the company's consistent ability to outperform the domestic pharma market growth and maintain high margins. The stock remains a solid mid-cap pharma play focused on branded formulations and operational efficiency.
Loading analysis...
RPG Life Sciences Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025
Consolidated and standalone results for the nine-month period were submitted to exchanges
The board meeting lasted three and a half hours, concluding at 6:30 p.m.
Statutory auditors have provided a Limited Review Report for the period
💼 Action for Investors
Investors should review the detailed profit and loss statements to assess margin trends and revenue growth compared to the previous year. Monitor the stock's price action in the coming sessions for the market's reaction to the specific earnings data.
Loading analysis...
RPG Life Sciences Board Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited held its board meeting on January 27, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The board reviewed both standalone and consolidated financial statements, ensuring compliance with SEBI Listing Obligations. The meeting, which lasted three and a half hours, concluded with the submission of the results and the statutory auditor's Limited Review Report. This is a routine but critical regulatory update for the third quarter of the 2025-26 fiscal year.
Key Highlights
Board approved unaudited standalone and consolidated financial results for Q3 FY26.
Financial results cover the nine-month period ending December 31, 2025.
Statutory Auditors issued a Limited Review Report on the financial statements.
The board meeting was conducted from 03:00 p.m. to 06:30 p.m. on January 27, 2026.
💼 Action for Investors
Investors should examine the detailed financial tables and auditor's report once released to evaluate the company's revenue growth and margin stability. Compare the Q3 performance against year-on-year benchmarks to assess long-term value.
Loading analysis...
RPG Life Sciences Incorporates Wholly Owned Subsidiary RPG Active Pharma Limited
RPG Life Sciences Limited has officially incorporated a new wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025. This move follows the company's prior intimation on December 15, 2025, regarding the strategic intent to form this entity. The new subsidiary is registered under CIN U21001MH2025PLC464091 and is expected to focus on specialized pharmaceutical operations. This structural expansion indicates a potential focus on the Active Pharmaceutical Ingredients (API) segment or a dedicated business vertical to drive future growth.
Key Highlights
Incorporated a 100% wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025
The new entity is registered under Corporate Identification Number (CIN) U21001MH2025PLC464091
The incorporation follows a prior regulatory intimation dated December 15, 2025
The move aligns with the company's long-term growth strategy within the pharmaceutical sector
💼 Action for Investors
Investors should monitor future announcements regarding the specific business objectives and capital expenditure plans for this new subsidiary. This expansion could potentially enhance the company's manufacturing capabilities and market reach in the API segment.
Loading analysis...
RPGLIFE appoints Amol Lone as CFO, to incorporate RPG Active Pharma
RPG Life Sciences has appointed Mr. Amol Lone as the Chief Financial Officer (CFO) effective December 15, 2025. The company will also incorporate a wholly-owned subsidiary, "RPG Active Pharma Limited," for manufacturing and marketing active pharmaceutical ingredients (API). RPGLIFE plans to transfer its existing API business, which contributed ₹90.24 crores (13.8%) to FY25 turnover, to the new subsidiary. An investment of up to ₹105 crore will be made in the WOS in one or more tranches.
Key Highlights
Amol Lone appointed as CFO effective December 15, 2025
API business contributed ₹90.24 crores to FY25 turnover
API business net worth as on March 31, 2025 was ₹90.61 crores
Investment of up to ₹105 crore in the new WOS
Consideration for API business transfer expected to be approximately ₹50 crore
💼 Action for Investors
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary, RPG Active Pharma Limited. Keep an eye on how the ₹105 crore investment impacts the company's growth and profitability.
Loading analysis...
RPGLIFE Board approves API business transfer to new wholly-owned subsidiary
RPG Life Sciences' board approved the transfer of its API business, which contributed ₹90.24 crore (13.8%) to FY25 turnover, to a new wholly-owned subsidiary (WOS). The net worth of the API business as of March 31, 2025, was ₹90.61 crore, representing 17.1% of the company's total net worth. The company will invest up to ₹105 crore in the WOS in tranches. The consideration for the transfer is expected to be approximately ₹50 crore.
Key Highlights
API business contributed ₹90.24 crore to FY25 turnover (13.8%).
Net worth of API business was ₹90.61 crore as of March 31, 2025 (17.1% of total).
Investment of up to ₹105 crore in the WOS.
Consideration for API business transfer expected to be approximately ₹50 crore.
💼 Action for Investors
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary. Keep an eye on how the ₹105 crore investment impacts the company's growth.